Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
2014 UK Consensus Guidelines — Hepatitis C Management and Direct-acting Anti-viral Therapy

These expert guidelines are sponsored by the Scottish government and take representative opinion from the British Society of Gastroenterology Liver Committee, British Association for the Study of Liver, the Scottish Society of Gastroenterology, the Scottish Viral Hepatitis group, the Scottish Viral Hepatitis Nurses group and the British Viral Hepatitis group.

Published
19 June 2014
From
Medscape (requires registration)
UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source: http://www.techtimes.com]

Published
19 June 2014
From
CDC
AbbVie all-oral hepatitis C therapy gets rapid EU review

The U.S. drugmaker said on Tuesday the move by the European Medicines Agency meant that, if approved, its regimen could be available in the European Union in the first quarter of 2015. U.S. regulators have also granted the product priority review.

Published
17 June 2014
From
Reuters
NICE rejection looms for Sovaldi

In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi (sofosbuvir) – and is currently not minded to recommend the treatment for NHS England funding.

Published
16 June 2014
From
Pharmafile
NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

In draft recommendations published today healthcare guidance body NICE is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C. “The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.”

Published
16 June 2014
From
NICE press release
Low uptake of HCV treatment in England will lead to substantial disease burden by 2035

Only 3% of patients with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of

Published
13 June 2014
By
Michael Carter
FDA lifts hold on Achillion's hepatitis C drug, shares jump

Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, sovaprevir, lifting a clinical hold that was imposed nearly a year ago. The company's shares soared as much 56 percent to $6.65 on the Nasdaq on Tuesday. Merck & Co's planned acquisition of Idenix Pharmaceuticals, announced on Monday, leaves Achillion as the only unencumbered company developing drugs that block a protein required by the hepatitis C virus to replicate.

Published
11 June 2014
From
Reuters
Why The Hepatitis C Cost Cutters May Have Already Lost

AbbVie’s chief executive has already made comments that were interpreted by reporters as meaning that he will not compete with Gilead on price. But the prospect of a hep C price war got even dimmer yesterday when Merck bought Idenix, a maker of hepatitis C drugs, for $3.9 billion in cash.

Published
11 June 2014
From
Forbes
Why is the $1,000 pill cheaper in the UK?

Will the pricing of hepatitis C treatment Sovaldi cause a crisis in American health care, and why is the price lower in the United Kingdom?

Published
10 June 2014
From
Columbia Journalism Review
Project Inform disappointed with direction of California hepatitis C testing bill

During this current legislative season, Project Inform sponsored California Senate Bill (SB) 1303, authored by Senator Norma Torres — a bill that would require healthcare practitioners in all primary care settings, except hospitals and emergency rooms, to make a one-time offer of a hepatitis C test to patients born between 1945 through 1965 (“Baby Boomers”) and other patients with identified risk factors for hepatitis C. The bill was modeled after legislation passed in New York State, based on hepatitis C testing recommendations by the Centers for Disease Control & Prevention (CDC) and the United States Preventive Services Task Force.

Published
10 June 2014
From
Project Inform

Filter by country